{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:13:02Z","timestamp":1762125182100},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T00:00:00Z","timestamp":1400112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11894-014-0394-0","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T02:42:46Z","timestamp":1400035366000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["New Pharmacological Treatments for the Management of Obesity"],"prefix":"10.1007","volume":"16","author":[{"given":"Ryan T.","family":"Hurt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jithinraj","family":"Edakkanambeth Varayil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon O.","family":"Ebbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,15]]},"reference":[{"key":"394_CR1","unstructured":"Organization WH. Obesity and overweight: Fact sheet. In: WHO Media centre WHO. 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/ . Accessed February 27, 2014 2014."},{"issue":"5","key":"394_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","volume":"307","author":"KM Flegal","year":"2012","unstructured":"Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491\u20137. doi: 10.1001\/jama.2012.39 . The most recent obesity epidemiology data in the United States.","journal-title":"JAMA"},{"key":"394_CR3","unstructured":"Prevention CfDCa. Morbidity and mortality weekly report. CDC, Atlanta, GA. 2010. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm59e0803a1.htm http:\/\/www.cdc.gov\/mmwr\/pdf\/wk\/mm59e0803.pdf . Accessed February 27 2014."},{"issue":"5","key":"394_CR4","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1177\/0148607111415110","volume":"35","author":"RT Hurt","year":"2011","unstructured":"Hurt RT, Frazier TH, McClave SA, Kaplan LM. Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum. JPEN J Parenter Enteral Nutr. 2011;35(5):4S\u201313S. doi: 10.1177\/0148607111415110 .","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"6","key":"394_CR5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/oby.2008.231","volume":"16","author":"DB Allison","year":"2008","unstructured":"Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16(6):1161\u201377.","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"394_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.NAJ.0000437102.45737.c7","volume":"113","author":"E Beal","year":"2013","unstructured":"Beal E. The pros and cons of designating obesity a disease: the new AMA designation stirs debate. Am J Nurs. 2013;113(11):18\u20139. doi: 10.1097\/01.NAJ.0000437102.45737.c7 .","journal-title":"Am J Nurs"},{"issue":"2","key":"394_CR7","first-page":"51S","volume":"6","author":"National Institutes of Health","year":"1998","unstructured":"National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report. Obes Res. 1998;6(2):51S\u2013209S.","journal-title":"Obes Res"},{"key":"394_CR8","author":"MD Jensen","year":"2013","unstructured":"Jensen MD, Ryan DH, Apovian CM, Loria CM, Ard JD, Millen BE, et al. AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013. doi: 10.1016\/j.jacc.2013.11.004 . Recently updated ambulatory obesity management guideline.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"394_CR9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.282.14.1353","volume":"282","author":"MK Serdula","year":"1999","unstructured":"Serdula MK, Mokdad AH, Williamson DF, Galuska DA, Mendlein JM, Heath GW. Prevalence of attempting weight loss and strategies for controlling weight. JAMA. 1999;282(14):1353\u20138.","journal-title":"JAMA"},{"issue":"12","key":"394_CR10","first-page":"780","volume":"6","author":"RT Hurt","year":"2010","unstructured":"Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol. 2010;6(12):780\u201392.","journal-title":"Gastroenterol. Hepatol"},{"issue":"5","key":"394_CR11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.amepre.2004.02.001","volume":"26","author":"J Kruger","year":"2004","unstructured":"Kruger J, Galuska DA, Serdula MK, Jones DA. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med. 2004;26(5):402\u20136.","journal-title":"Am J Prev Med"},{"issue":"9","key":"394_CR12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa0804748","volume":"360","author":"FM Sacks","year":"2009","unstructured":"Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859\u201373.","journal-title":"N Engl J Med"},{"issue":"21","key":"394_CR13","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMct067019","volume":"356","author":"EJ DeMaria","year":"2007","unstructured":"DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356(21):2176\u201383. doi: 10.1056\/NEJMct067019 .","journal-title":"N Engl J Med"},{"key":"394_CR14","author":"PR Schauer","year":"2014","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes\u20143-year outcomes. N Engl J Med. 2014. doi: 10.1056\/NEJMoa1401329 .","journal-title":"N Engl J Med"},{"issue":"17","key":"394_CR15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMe1202443","volume":"366","author":"P Zimmet","year":"2012","unstructured":"Zimmet P, Alberti KG. Surgery or medical therapy for obese patients with type 2 diabetes? N Engl J Med. 2012;366(17):1635\u20136. doi: 10.1056\/NEJMe1202443 .","journal-title":"N Engl J Med"},{"issue":"4","key":"394_CR16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.7326\/0003-4819-134-4-200102200-00011","volume":"134","author":"LK Khan","year":"2001","unstructured":"Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescription weight loss pills among U.S. adults in 1996-1998. Ann Intern Med. 2001;134(4):282\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"394_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.gtc.2010.01.001","volume":"39","author":"LM Kaplan","year":"2010","unstructured":"Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North Am. 2010;39(1):69\u201379. doi: 10.1016\/j.gtc.2010.01.001 .","journal-title":"Gastroenterol Clin North Am"},{"issue":"17","key":"394_CR18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577\u20139. doi: 10.1056\/NEJMp1211277 .","journal-title":"N Engl J Med"},{"issue":"5","key":"394_CR19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1992.76","volume":"51","author":"M Weintraub","year":"1992","unstructured":"Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51(5):642\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"394_CR20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine\u2013phentermine. N Engl J Med. 1997;337(9):581\u20138. doi: 10.1056\/NEJM199708283370901 .","journal-title":"N Engl J Med"},{"issue":"10","key":"394_CR21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0899-9007(00)00424-X","volume":"16","author":"GA Bray","year":"2000","unstructured":"Bray GA. A concise review on the therapeutics of obesity. Nutrition. 2000;16(10):953\u201360.","journal-title":"Nutrition"},{"issue":"1","key":"394_CR22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356(1):6\u20139. doi: 10.1056\/NEJMp068265 .","journal-title":"N Engl J Med"},{"issue":"1","key":"394_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-0327(90)90008-V","volume":"19","author":"P Mitchell","year":"1990","unstructured":"Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord. 1990;19(1):43\u201351.","journal-title":"J Affect Disord"},{"key":"394_CR24","unstructured":"FDA USFaDA. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). In: withdrawal of fen-phen. FDA. 1997. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm179871.htm . Accessed February 27 2014."},{"issue":"6","key":"394_CR25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","volume":"56","author":"W McNeely","year":"1998","unstructured":"McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093\u2013124.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"394_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/dmrr.2349","volume":"28","author":"V Hainer","year":"2012","unstructured":"Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28 Suppl 2:8\u201320. doi: 10.1002\/dmrr.2349 .","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"394_CR27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.fertnstert.2007.05.002","volume":"89","author":"A Lindholm","year":"2008","unstructured":"Lindholm A, Bixo M, Bjorn I, Wolner-Hanssen P, Eliasson M, Larsson A, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2008;89(5):1221\u20138. doi: 10.1016\/j.fertnstert.2007.05.002 .","journal-title":"Fertil Steril"},{"issue":"5","key":"394_CR28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2006.05.008","volume":"28","author":"LM Garcia-Morales","year":"2006","unstructured":"Garcia-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2006;28(5):770\u201382. doi: 10.1016\/j.clinthera.2006.05.008 .","journal-title":"Clin Ther"},{"issue":"9","key":"394_CR29","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.clinthera.2004.09.017","volume":"26","author":"L Sanchez-Reyes","year":"2004","unstructured":"Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther. 2004;26(9):1427\u201335. doi: 10.1016\/j.clinthera.2004.09.017 .","journal-title":"Clin Ther"},{"issue":"3","key":"394_CR30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","volume":"4","author":"GA Bray","year":"1996","unstructured":"Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4(3):263\u201370.","journal-title":"Obes Res"},{"issue":"39","key":"394_CR31","first-page":"2339","volume":"107","author":"S Rossner","year":"2010","unstructured":"Rossner S. [The trial that killed a drug]. Lakartidningen. 2010;107(39):2339.","journal-title":"Lakartidningen"},{"key":"394_CR32","doi-asserted-by":"crossref","first-page":"c824","DOI":"10.1136\/bmj.c824","volume":"340","author":"G Williams","year":"2010","unstructured":"Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824. doi: 10.1136\/bmj.c824 .","journal-title":"BMJ"},{"issue":"5","key":"394_CR33","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","volume":"143","author":"E Colman","year":"2005","unstructured":"Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380\u20135.","journal-title":"Ann Intern Med"},{"issue":"4","key":"394_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MJT.0b013e3181d070d7","volume":"18","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther. 2011;18(4):292\u20139. doi: 10.1097\/MJT.0b013e3181d070d7 .","journal-title":"Am J Ther"},{"issue":"12","key":"394_CR35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/erc.10.125","volume":"8","author":"H Bays","year":"2010","unstructured":"Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777\u2013801. doi: 10.1586\/erc.10.125 .","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"394_CR36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ncpgasthep0092","volume":"2","author":"GA Bray","year":"2005","unstructured":"Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol. 2005;2(2):89\u201395. doi: 10.1038\/ncpgasthep0092 .","journal-title":"Nat. Clin. Pract Gastroenterol. Hepatol"},{"key":"394_CR37","author":"J Jordan","year":"2014","unstructured":"Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014. doi: 10.1097\/HJH.0000000000000145 .","journal-title":"J Hypertens"},{"issue":"1","key":"394_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32\u201341. doi: 10.1002\/1098-2396(20010101) .","journal-title":"Synapse"},{"issue":"4","key":"394_CR39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11936-007-0021-6","volume":"9","author":"H Bays","year":"2007","unstructured":"Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options in Cardiovasc Med. 2007;9(4):259\u201371.","journal-title":"Curr. Treat. Options in Cardiovasc. Med"},{"issue":"12","key":"394_CR40","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","volume":"19","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351\u201360. doi: 10.1038\/oby.2011.94 .","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"394_CR41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ijo.2013.74","volume":"38","author":"EJ Hendricks","year":"2014","unstructured":"Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38(2):292\u20138. doi: 10.1038\/ijo.2013.74ijo201374 .","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"394_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270\u20139.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"394_CR43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","volume":"281","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2\u00a0years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235\u201342.","journal-title":"JAMA"},{"issue":"2","key":"394_CR44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","volume":"9","author":"J Hauptman","year":"2000","unstructured":"Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160\u20137.","journal-title":"Arch Fam Med"},{"issue":"7","key":"394_CR45","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","volume":"25","author":"JM Miles","year":"2002","unstructured":"Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123\u20138.","journal-title":"Diabetes Care"},{"issue":"9123","key":"394_CR46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167\u201372.","journal-title":"Lancet"},{"issue":"2","key":"394_CR47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/eb-2012-100958","volume":"16","author":"L Veerman","year":"2013","unstructured":"Veerman L. Orlistat reduces weight but its cost-effectiveness remains unclear. Evid-Based Nurs. 2013;16(2):56\u20137. doi: 10.1136\/eb-2012-100958 .","journal-title":"Evid.-Based Nurs"},{"issue":"7631","key":"394_CR48","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194\u20139. doi: 10.1136\/bmj.39385.413113.25 .","journal-title":"BMJ"},{"issue":"7","key":"394_CR49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","volume":"155","author":"ES Leblanc","year":"2011","unstructured":"Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(7):434\u201347.","journal-title":"Ann Intern Med"},{"issue":"7","key":"394_CR50","first-page":"703","volume":"171","author":"MA Weir","year":"2011","unstructured":"Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171(7):703\u20134. doi: 10.1001\/archinternmed.2011.103 .","journal-title":"Arch Intern Med"},{"issue":"4","key":"394_CR51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000341589","volume":"5","author":"M Morris","year":"2012","unstructured":"Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obesity Facts. 2012;5(4):485\u201394. doi: 10.1159\/000341589 .","journal-title":"Obesity Facts"},{"key":"394_CR52","unstructured":"Orlistat: hepatitis and oxalate nephropathy. Prescrire international. 2012;21(125):71."},{"issue":"8","key":"394_CR53","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","volume":"21","author":"PA Hollander","year":"1998","unstructured":"Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288\u201394.","journal-title":"Diabetes Care"},{"key":"394_CR54","unstructured":"FDA. FDA approves Belviq to treat some overweight or obese adults. In: FDA NEWS RELEASE. 2012. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm309993.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=lorcaserin&utm_content=4 . Accessed February 27 2014."},{"issue":"7\u20138","key":"394_CR55","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1345\/aph.1R779","volume":"47","author":"JW Fleming","year":"2013","unstructured":"Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine\/topiramate. Ann Pharmacother. 2013;47(7\u20138):1007\u201316. doi: 10.1345\/aph.1R779 .","journal-title":"Ann Pharmacother"},{"issue":"2\u20133","key":"394_CR56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00213-010-1887-7","volume":"213","author":"V Katsidoni","year":"2011","unstructured":"Katsidoni V, Apazoglou K, Panagis G. Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacol. 2011;213(2\u20133):337\u201354. doi: 10.1007\/s00213-010-1887-7 .","journal-title":"Psychopharmacol"},{"issue":"18","key":"394_CR57","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2174\/156802606778522131","volume":"6","author":"MJ Bubar","year":"2006","unstructured":"Bubar MJ, Cunningham KA. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem. 2006;6(18):1971\u201385.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"394_CR58","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"WJ Thomsen","year":"2008","unstructured":"Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577\u201387. doi: 10.1124\/jpet.107.133348 .","journal-title":"J. Pharmacol. Exp. Ther"},{"issue":"4","key":"394_CR59","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCIMAGING.112.000128","volume":"6","author":"NJ Weissman","year":"2013","unstructured":"Weissman NJ, Sanchez M, Koch GG, Smith SR, Shanahan WR, Anderson CM. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560\u20137. doi: 10.1161\/CIRCIMAGING.112.000128 .","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"394_CR60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245\u201356. doi: 10.1056\/NEJMoa0909809 .","journal-title":"N Engl J Med"},{"issue":"10","key":"394_CR61","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067\u201377. doi: 10.1210\/jc.2011-1256 . A large study demonstrating a significant weight loss benefit of lorcaserin.","journal-title":"J. Clin. Endocrinol Metab"},{"issue":"7","key":"394_CR62","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PM O'Neil","year":"2012","unstructured":"O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426\u201336. doi: 10.1038\/oby.2012.66oby201266 . study demonstrating the effect of lorcaserin for weight loss in patients with type 2 diabetes mellitis.","journal-title":"Obesity (Silver Spring)"},{"key":"394_CR63","unstructured":"U.S Department of Justice DEAOodc. Schedules of controlled substances: placement of lorcaserin into schedule IV. Drug Enforcement Administration, Department of Justice. Springfield. 2012. http:\/\/www.deadiversion.usdoj.gov\/fed_regs\/rules\/2012\/fr1219.htm . Accessed April, 7 2014."},{"issue":"15","key":"394_CR64","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2165\/11640860-000000000-00000","volume":"72","author":"F Cameron","year":"2012","unstructured":"Cameron F, Whiteside G, McKeage K. Phentermine and topiramate extended release (Qsymia): first global approval. Drugs. 2012;72(15):2033\u201342. doi: 10.2165\/11640860-000000000-00000 .","journal-title":"Drugs"},{"issue":"9786","key":"394_CR65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(11)61080-5","volume":"378","author":"RB Malgarini","year":"2011","unstructured":"Malgarini RB, Pimpinella G. Phentermine plus topiramate in the treatment of obesity. Lancet. 2011;378(9786):125\u20136. doi: 10.1016\/S0140-6736(11)61080-5 . author reply 6-7.","journal-title":"Lancet"},{"key":"394_CR66","unstructured":"FDA USFaDA. FDA approves weight-management drug Qsymia. FDA. 2012. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm312468.htm . Accessed February 27 2014."},{"issue":"6","key":"394_CR67","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722\u201333. doi: 10.1038\/oby.2003.102 .","journal-title":"Obes Res"},{"issue":"11","key":"394_CR68","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord : J Int Assoc Study of Obesity. 2004;28(11):1399\u2013410. doi: 10.1038\/sj.ijo.0802783 .","journal-title":"Int. J. Obes. Relat. Metab. Disord : J. Int. Assoc Study of Obesity"},{"issue":"Suppl 1","key":"394_CR69","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41 Suppl 1:S3\u20139.","journal-title":"Epilepsia"},{"issue":"9774","key":"394_CR70","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352. doi: 10.1016\/S0140-6736(11)60205-5 . The combinations of phentermine and topiramate was found to have significant weight reduction in overweight\/ obese subjects.","journal-title":"Lancet"},{"issue":"2","key":"394_CR71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330\u201342. doi: 10.1038\/oby.2011.330 .","journal-title":"Obesity"},{"issue":"2","key":"394_CR72","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308. doi: 10.3945\/ajcn.111.024927 . A two year extension to the CONQUER study which did not demonstrate any cardiovascular abnormality in the phentermine\/topiramate compared to placebo.","journal-title":"Am. J. Clin. Nutr"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-014-0394-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-014-0394-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-014-0394-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:09:30Z","timestamp":1559434170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-014-0394-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,15]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s11894-014-0394-0","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,15]]},"article-number":"394"}}